Josep Tabernero

Research interests

Publications

• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Nature · 2021 · https://doi.org/10.1038/s41586-021-04161-3

• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

  JAMA Oncology · 2020 · https://doi.org/10.1001/jamaoncol.2020.3370

• Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.06.022

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908075

• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx175

• Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

  Science · 2017 · 10.1126/science.aal5240

• Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

  Nature reviews. Cancer · 2017 · 10.1038/nrc.2016.126

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70127-0

• The consensus molecular subtypes of colorectal cancer

  Nature Medicine · 2015 · https://doi.org/10.1038/nm.3967

• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

  Nature Communications · 2015 · 10.1038/ncomms9839

• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-15-0369

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1502309

• Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414325

• Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1304369

• Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1305275

• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

  The Lancet · 2013 · 10.1016/s0140-6736(13)61719-5

• First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

  Cancer Discovery · 2013 · 10.1158/2159-8290.cd-12-0429

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61900-x

• Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.42.8201

• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

  Annals of Oncology · 2012 · 10.1093/annonc/mds236

• Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

  Genome Research · 2011 · 10.1101/gr.126573.111

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70130-3

• Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.27.4860

• The landscape of somatic copy-number alteration across human cancers

  Nature · 2010 · https://doi.org/10.1038/nature08822

• Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.20.6771

• Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa032709

Current projects

No projects listed.